Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Company Overview

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Key Stats

• Today's Range: $9.32 to $9.87
• 50-Day Range: $9.67 to $15.76
• 52-Week Range: $4.88 to $19.58
• Volume: 77,987 shs
• Average Volume: 48,896 shs
• Market Capitalization: $212.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.80
• Consensus Rating: Buy

AARD Stock Analysis - Frequently Asked Questions

How have AARD shares performed this year?

Aardvark Therapeutics' stock was trading at $13.30 at the start of the year. Since then, AARD stock has decreased by 26.5% and is now trading at $9.77.

How were Aardvark Therapeutics' earnings last quarter?

Aardvark Therapeutics, Inc. (NASDAQ:AARD) posted its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.14.

When did Aardvark Therapeutics IPO?

Aardvark Therapeutics (AARD) raised $100 million in an initial public offering on Friday, February 14th 2025. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets served as the underwriters for the IPO.

When did the company's lock-up period expire?

Aardvark Therapeutics's lock-up period expired on Tuesday, August 12th. Aardvark Therapeutics had issued 5,888,000 shares in its initial public offering on February 13th. The total size of the offering was $94,208,000 based on an initial share price of $16.00. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are Aardvark Therapeutics' major shareholders?

Aardvark Therapeutics' top institutional investors include Adage Capital Partners GP L.L.C. (0.81%), Geode Capital Management LLC (0.63%), Bank of America Corp DE (0.04%) and New York State Common Retirement Fund (0.03%). Insiders that own company stock include Tien-Li Lee and Nelson Sun.
View institutional ownership trends.

How do I buy shares of Aardvark Therapeutics?

Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AARD
• Previous Symbol: NASDAQ:AARD
• CIK: 1774857
• Web: N/A
• Phone: (858) 225-7696
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aardvark Therapeutics: $32.80
• High Price Target: $50.00
• Low Price Target: $19.00
• Potential Upside/Downside: +235.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.04
• Quick Ratio: 14.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.31 per share
• Price / Book: 1.55

Miscellaneous

• Outstanding Shares: 21,700,000
• Free Float: N/A
• Market Cap: $212.01 million
• Optionable: N/A
• Beta: N/A